Fulgent Genetics Financials
FLGT Stock | USD 16.57 0.27 1.60% |
Fulgent |
Understanding current and past Fulgent Genetics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Fulgent Genetics' financial statements are interrelated, with each one affecting the others. For example, an increase in Fulgent Genetics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Fulgent Genetics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Fulgent Genetics. Check Fulgent Genetics' Beneish M Score to see the likelihood of Fulgent Genetics' management manipulating its earnings.
Fulgent Genetics Stock Summary
Fulgent Genetics competes with Illumina, T2 Biosystms, Agilent Technologies, Mettler Toledo, and Waters. Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California. Fulgent Genetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 645 people.Specialization | Healthcare, Diagnostics & Research |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US3596641098 |
CUSIP | 359664109 |
Location | California; U.S.A |
Business Address | 4399 Santa Anita |
Sector | Health Care Providers & Services |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.fulgentgenetics.com |
Phone | 626 350 0537 |
Currency | USD - US Dollar |
Fulgent Genetics Key Financial Ratios
Return On Equity | -0.14 | ||||
Return On Asset | -0.0415 | ||||
Target Price | 27.67 | ||||
Beta | 1.51 |
Fulgent Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Fulgent Genetics's current stock value. Our valuation model uses many indicators to compare Fulgent Genetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Fulgent Genetics competition to find correlations between indicators driving Fulgent Genetics's intrinsic value. More Info.Fulgent Genetics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Fulgent Genetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Fulgent Genetics Systematic Risk
Fulgent Genetics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Fulgent Genetics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Fulgent Genetics correlated with the market. If Beta is less than 0 Fulgent Genetics generally moves in the opposite direction as compared to the market. If Fulgent Genetics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Fulgent Genetics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Fulgent Genetics is generally in the same direction as the market. If Beta > 1 Fulgent Genetics moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Fulgent Genetics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Fulgent has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Fulgent Genetics' financials are consistent with your investment objective using the following steps:- Review Fulgent Genetics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Fulgent Genetics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Fulgent Genetics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Fulgent Genetics' stock is overvalued or undervalued.
Fulgent Genetics Thematic Clasifications
Fulgent Genetics is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Healthcare | View |
Fulgent Genetics February 7, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Fulgent Genetics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Fulgent Genetics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Fulgent Genetics based on widely used predictive technical indicators. In general, we focus on analyzing Fulgent Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Fulgent Genetics's daily price indicators and compare them against related drivers.
Information Ratio | (0.13) | |||
Maximum Drawdown | 11.46 | |||
Value At Risk | (3.80) | |||
Potential Upside | 3.49 |
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.